Jörg Scheuermann: Catalogue data in Autumn Semester 2021 |
| Name | Prof. Dr. Jörg Scheuermann |
| Field | Pharmaceutical Sciences |
| Address | Inst. f. Pharmazeutische Wiss. ETH Zürich, HCI G 396.4 Vladimir-Prelog-Weg 1-5/10 8093 Zürich SWITZERLAND |
| Telephone | +41 44 633 77 74 |
| joerg.scheuermann@pharma.ethz.ch | |
| URL | https://del-technology.ethz.ch/ |
| Department | Chemistry and Applied Biosciences |
| Relationship | Adjunct Professor and Privatdozent |
| Number | Title | ECTS | Hours | Lecturers | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 511-0000-00L | Drug Discovery and Development  Only for MSc Pharmaceutical Sciences. | 2 credits | 1G + 1S | J. Hall, U. Thibaut, K.‑H. Altmann, M. Arand, J. Scheuermann, R. Schibli, H. U. Zeilhofer | ||||||||||||||||||||
| Abstract | This course provides an overview over the concepts and processes employed in today's drug discovery and development. It has an introductory character but will also provide more detailed insights employing real life examples. The course combines lectures and interactive elements with active participation of the students. | |||||||||||||||||||||||
| Learning objective | Students - Understand the drug discovery process and can explain major approaches and relevant technical terms (for details see lecture notes). - Understand and appreciate the content and timing of drug development process steps, development phases and decision criteria. - Understand the concepts underlying drug product development through all the phases from preclinical and clinical development to regulatory submission, approval and market launch. - Can differentiate between small molecule drug development and biological drug development. - Understand the most important differences between legal and regulatory requirements for drug development and approval for the major markets EU and USA. | |||||||||||||||||||||||
| Content | Course unit comprises weekly lectures covering the early phases of target and drug discovery (535-0901-01 S "From A to Z in Drug Discovery and Development I") with group work in the area of Drug Development (511-0000-00 G). Group work is 2 full days (Days 1 and 2) and comprises: introduction to the entire suite of drug product development processes in the pharmaceutical industry, covering: preclinical research and development, clinical development, regulatory processes and market launch. R&D support processes such as project management, quality management, pharmacovigilance and pharmacoeconomics will be covered as well as organizational and governance aspects of the pharmaceutical industry. In addition, important success factors for a later career in the pharmaceutical industry will be discussed and highlighted at the end of the course. | |||||||||||||||||||||||
| Lecture notes | Will be published on "mystudies" | |||||||||||||||||||||||
| Literature | G. Nahler (Hrsg.) Dictionary of pharmaceutical medicine, Springer, Wien, 2013 (3rd edition) Further readings will be listed in the lecture notes. | |||||||||||||||||||||||
| Prerequisites / Notice | This course provides the essential basic knowledge required for the industry-specific modules of the spring semester. Safety conceptt: https://chab.ethz.ch/studium/bachelor1.html | |||||||||||||||||||||||
| 511-1003-00L | Gene Technology (Crash Course) Only for Pharmaceutical Sciences MSc. Obligatory course if assigned by the Admission committee. | 1 credit | 1S | J. Scheuermann | ||||||||||||||||||||
| Abstract | The course enables the student to understand and and apply the general concepts of gene technology, including recombinant DNA technology and its application in genomics, transcriptomics and proteomics. Protein cloning, expression and modifications and bimolecular interactions will be discussed. The concept of display technology and its applications in the field of drug discovery will be presented. | |||||||||||||||||||||||
| Learning objective | The students remember and understand: 1. The tools of recombinant DNA technology 2. Next generation sequencing approaches and their relevance for -omics projects 3. Protein cloning, expression, modification/labelling and oligomerization 4. Thermodynamic and kinetic affinity constants in bimolecular reactions 5. Basic structure of the antibody molecule 6. Concepts of antibody phage technology and antibody engineering 7. Construction of antibody-, peptide- or small molecule libraries and affintiy-based selection methodologies | |||||||||||||||||||||||
| Content | I) Genomics: recombinant DNA technology methods to sequence genomes application to human biology Transcriptomics / Proteomics II) Proteins: protein cloning and expression homo- and heterodimerization chemical modifications and radioactive labelling detection of bimolecular interactions affinity constant and experimental measurement kinetic association and dissociation constants III) Display technology: the antibody molecule, CDRs, basics of antibody engineering antibody phage display and selection methodologies construction of antibody libraries other display technologies (peptide display, DNA-encoded chemical libraries) | |||||||||||||||||||||||
| Lecture notes | slides and script used for the course and literature for reading and discussions will be made available online. | |||||||||||||||||||||||
| Literature | dedicated chapters of: S.B. Primrose and R.M. Twyman 'Principles of Gene Manipulation and Genomics', 7th ed. (2006) Blackwell Science dedicated articles will be announced | |||||||||||||||||||||||
| Prerequisites / Notice | admission to MSc in Pharmaceutical Sciences | |||||||||||||||||||||||
| 535-0001-00L | Introduction to Pharmaceutical Sciences I | 2 credits | 2V | J. Hall, K.‑H. Altmann, M. Detmar, C. Halin Winter, J.‑C. Leroux, U. Quitterer, J. Scheuermann, R. Schibli, H. U. Zeilhofer | ||||||||||||||||||||
| Abstract | First identification with Pharmaceutical Sciences; motivation for profiling in the Natural Sciences, which are focused on within the first two years as a preparation for the specialized studies; sensitization for the duties and the responsibilities of a person with a federal diploma in Pharmacy; information about job opportunities. | |||||||||||||||||||||||
| Learning objective | First identification with Pharmaceutical Sciences; motivation for profiling in the Natural Sciences as a preparation for the specialized studies; sensitization for the duties and the responsibilities of a person with a federal diploma in Pharmacy; information about job opportunities. | |||||||||||||||||||||||
| Content | Introduction to Pharmaceutical Sciences by selected milestones of research and development. Overview on research activities at the Institute of Pharmaceutical Sciences that is focussed on drug delivery and development (from concepts to prototypes). Sensitization for communication skills and information management. Demonstration of job opportunities in community pharmacies, in the hospital, in industry, and in the public sector by experts in the different fields. | |||||||||||||||||||||||
| Lecture notes | Handouts for individual lectures. | |||||||||||||||||||||||
| Prerequisites / Notice | Interactive teaching | |||||||||||||||||||||||
| 535-0011-00L | Drug Seminar The course is reserved for students registered in the Master's programme in Pharmacy or in Pharmaceutical Sciences | 5 credits | 9S | A. Burden, K.‑H. Altmann, M. Detmar, K. Eyer, C. Halin Winter, J. Hall, S.‑D. Krämer, J.‑C. Leroux, C. Müller, V. I. Otto, U. Quitterer, J. Scheuermann, R. Schibli, C. Steuer | ||||||||||||||||||||
| Abstract | The course provides a platform for the investigation, presentation and discussion of a topic with relevance to the field of pharmaceutical sciences. Students work in small groups on a chosen topic, they write a mini-review and present their work on a one day symposium. | |||||||||||||||||||||||
| Learning objective | The main objectives of this course are: - students develop their scientific reflection (Critical Thinking) and working skills by working independently on a relevant pharmaceutical topic - students gain in-depth knowledge of the topic investigated - students train their scientific writing and presentation skills - students train their ability to plan a project and work in a team | |||||||||||||||||||||||
| Content | The Course Drug Seminar takes place during the first 7 weeks of the 1. Master semester. It is a compulsory course of the MSc Pharmacy curriculum and an elective course in the MSc PharmSciences. The course provides a platform for the investigation, presentation and discussion of a topic with relevance to the field of pharmaceutical sciences. During the course, students work in small teams on a topic of their choice and elaborate a written mini-review and an oral presentation. Each team is tutored by a lecturer of the Institute of Pharmaceutical Sciences. The work is mainly based on literature search / review, but may also involve conducting interviews or site visits, if appropriate. The final presentations of all groups will take place in the framework of a dedicated Symposium held in the middle of the semester. | |||||||||||||||||||||||
| Prerequisites / Notice | Only for students of MSc Pharmacy and MSc Pharmaceutical Sciences. | |||||||||||||||||||||||
| 535-0239-00L | Practical Course in Medicinal Chemistry | 3 credits | 7P | J. Hall, M. Detmar, C. Halin Winter, J. Scheuermann | ||||||||||||||||||||
| Abstract | The course comprises experiments relating to concepts of medicinal chemistry including statistical processing, fitting of experimental data, computer modeling of protein structures, experimental measurement of affinity constants and kinetic dissociation constants for protein ligands. The chemical stability of a drug will be studied. Basic gene cloning and protein expression will be introduced. | |||||||||||||||||||||||
| Learning objective | Knowledge of experimental methods in drug discovery and development | |||||||||||||||||||||||
| Content | Characterisation of the biophysical and biological properties of drugs. | |||||||||||||||||||||||
| Lecture notes | Scripts | |||||||||||||||||||||||
| Literature | Original literature | |||||||||||||||||||||||
| Prerequisites / Notice | Requirements: Laboratory course in Pharmaceutical Anaytics; Lecture Medicinal Chemistry I in the same semester or earlier. Safety conceptt: https://chab.ethz.ch/studium/bachelor1.html | |||||||||||||||||||||||
| 535-0300-00L | Molecular Mechanisms of Drug Actions and Targets Number of participants limited to 24. | 2 credits | 1V | J. Scheuermann | ||||||||||||||||||||
| Abstract | On average one drug per year is withdrawn from the market. Using selected examples of such drug failures, the course aims at analyzing and discussing the present explanations of drug actions as well as the design and predictive power of animal models and clinical trials. In addition, the ethical, societal, and economical expectations in new drugs shall be reflected and discussed. | |||||||||||||||||||||||
| Learning objective | To develop a critical understanding of the relevance and limitations of the current approaches to explaining and anticipating drug effects. To critically appraise the ethical, societal, economical and political expectations in the development of new drugs. | |||||||||||||||||||||||
| Content | In December 2006, Pfizer stopped a large phase III study on the use of Torcetrapib for the prevention of atherosclerosis and cardiovascular disease. 800 million $ in development costs and 21 billion $ in stocks were annihilated overnight. The failure of Torcetrapib has pinpointed the limitations of an extremely reductionist view of atherosclerosis and it's prevention by drug therapy. It has also highlighted what high expectations we have in a safe and wide applicability of drugs and of their economical success. Torcetrapib is not a single case. In the last 10 years, on average one drug per year was withdrawn from the market due to lack of efficacy, unexpected side effects or toxicity. This clearly shows that the common investigations and the modern understanding of drug actions are often not sufficient to predict the effects a drug will have in large patient populations. These are the topics of the present course. Using three particularly informative examples of drug failures, the problems encountered and the concepts and informative value of preclinical and clinical studies will be analyzed and discussed. Furthermore, the ethical, societal, economical and political expectations in new drugs shall be reflected. | |||||||||||||||||||||||
| Lecture notes | Lecture slides and literature for reading and discussions will be available online. | |||||||||||||||||||||||
| Prerequisites / Notice | Requirements: basic knowledge in Medicinal Chemistry and Pharmacology. Ability to read and understand scientific publications written in English. | |||||||||||||||||||||||
| 535-0810-00L | Gene Technology | 2 credits | 2G | K. Eyer, J. Scheuermann | ||||||||||||||||||||
| Abstract | The course gives a description and summary of the field of gene technology and its pharmaceutical applications. The course focuses on important methods and technologies and their application for genomic, transcriptomic and proteomic analyses in human biology. | |||||||||||||||||||||||
| Learning objective | The course gives an overview of current state-of-the art and advancement in the fields of gene technology. Herein, the course focuses on genomic, transcriptomic and proteomic analysis and their uses in drug discovery and biomedical applications. The course is structured into lectures and practical examples drawn from the research field. Upon completion, the students are familiar and know current state-of-the art of methods and applications, but are also able to classify, contrast and apply different strategies and methods within the field of gene technology. The course is suited for advanced undergraduate and early graduate students in pharmaceutical sciences or related fields. | |||||||||||||||||||||||
| Content | I) Genomics and transcriptomics Methods and Techniques: • Recombinant DNA technology • Next generation sequencing methods, sequencing of genomes • CRISPR technology Application to human biology: • Functional genomics/transcriptomics • Principles of cancer, genetic diseases • Therapies: cell-based therapies/gene therapies/DNA and RNA vaccination II) Proteomics Methods and Techniques: • Protein cloning and expression • The antibody molecule • Measurement and determination of biomolecular interactions • Protein characterization and engineering • Modifications and radioactive labelling Application to human biology: • Protein therapeutics • Proteomic approaches for identification of novel disease-related targets and biomarkers III) Drug discovery: Protein-based libraries •Immune repertoire mining •Display and selection technologies 1. antibody phage display 2. other polypeptide display technologies 3. small-molecules display: DNA-encoded chemical libraries | |||||||||||||||||||||||
| Lecture notes | The lecture series follows the above-described content, and the students are provided with the lecture slides and additional notes. The additional notes are needed for the in-depth study of the individual topics, and to set the frame and content of the in-class group work of the chosen examples. | |||||||||||||||||||||||
Competencies |
| |||||||||||||||||||||||
| 535-0901-00L | From A to Z in Drug Discovery and Development | 1 credit | 2S | J. Hall, K.‑H. Altmann, M. Arand, J. Scheuermann, R. Schibli, H. U. Zeilhofer | ||||||||||||||||||||
| Abstract | The lecture series takes place at the ETH Hönggerberg and covers a variety of major activities involved in drug discovery: selecting drug targets, technologies used in drug discovery, small, medium and large drugs, objectives of the medicinal chemist, assessing drug safety, principles of personalized medicine, designing clinical trials, how intellectual property is protected, as well as others. | |||||||||||||||||||||||
| Learning objective | The objective of the course is to gain a global understanding of most of the important phases in the discovery and development of modern synthetic and biological drugs, from the first activities to clinical trials. The lecture is intended for students that have an interest in the area and/or may consider a career working in drug discovery. This lecture course complements knowledge and experience gained in the research project performed by the PhD student. | |||||||||||||||||||||||
| Content | Thirteen two hour lectures for life-science PhD students and students of the Pharmaceutical Sciences Master, given by experts from the ETH, UZH, USZ and the pharmaceutical industry. Introduction to the modern drug discovery process - Principles of drug pharmacokinetics and drug metabolism - Computer sciences in drug discovery - Drug targets - In vitro methods in drug discovery - Natural products in drug discovery - Medicinal chemistry: Chemical lead selection/optimization - Antibodies and therapeutic proteins: Targets and drugs - In vivo molecular imaging in drug discovery - Drug formulation: Key development consideration, Current new APIs challenges and FDA rising standards - Preclinical safety, adverse drug events and drug-drug interactions - Clinical development steps including trial design - Intellectual property in drug discovery and development | |||||||||||||||||||||||
| Lecture notes | Scripts to be uploaded into ILIAS | |||||||||||||||||||||||
| Literature | To be distributed during the lecture | |||||||||||||||||||||||
| Prerequisites / Notice | Formally none, but a basic understanding in biochemistry, physiology and chemistry is highly desirable as it will certainly help to get the most from the lectures. | |||||||||||||||||||||||